HLS Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
HLS Therapeutics has a total shareholder equity of $97.7M and total debt of $86.7M, which brings its debt-to-equity ratio to 88.8%. Its total assets and total liabilities are $209.1M and $111.4M respectively.
Key information
88.8%
Debt to equity ratio
US$86.74m
Debt
Interest coverage ratio | n/a |
Cash | US$21.95m |
Equity | US$97.70m |
Total liabilities | US$111.36m |
Total assets | US$209.06m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: HLTR.F's short term assets ($44.1M) exceed its short term liabilities ($26.7M).
Long Term Liabilities: HLTR.F's short term assets ($44.1M) do not cover its long term liabilities ($84.7M).
Debt to Equity History and Analysis
Debt Level: HLTR.F's net debt to equity ratio (66.3%) is considered high.
Reducing Debt: HLTR.F's debt to equity ratio has increased from 62.5% to 88.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable HLTR.F has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: HLTR.F is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 11.9% per year.